Insights into Nutrition for Patients with Neuroendocrine Cancer

Q&A with Rachel C. Miller

Registered Dietitian Consultant at University of Kentucky Markey Cancer Center

After a neuroendocrine tumor (NET) diagnosis, many patients wonder what changes need to be made to their diet or if there is one food that is suitable for all NET patients. Nutrition can play an important role in managing symptoms and getting back to living your life, but it can be difficult to find the right diet. We spoke with Rachel C. Miller, Registered Dietitian Consultant at University of Kentucky Markey Cancer Center to answer your questions and share her insights into nutrition for NETs patients.

  1. To start off, what you do for a living and what’s a typical day in the life?

I’ve always been interested in the science of food and nutrition. Eating is such an inherent part of our lives (and who doesn’t love food?). I’ve been able to combine my passion for health and wellness with the scientific aspect of nutrition. The more I learned about it, the more I wanted to follow it as a career to help others.

I’m currently an outpatient dietitian consultant at the Markey Cancer Center, where I work with oncology patients across the board. Because there are oncologists that specialize in neuroendocrine tumors at our center, a lot of the patients I see have this disease. Cancer is complex, but NETs are especially difficult to navigate because a patient’s diet and nutritional needs are directly impacted by the disease and its symptoms.

I see patients at all points during the cancer treatment process: before, during and after. No two days are the same, and I go where the need is greatest. One minute, I could be consulting with patients undergoing chemo or radiation, and the next, I’m speaking with a patient on the phone for a follow-up consultation. I’ll see any and every patient that needs our help and work closely with patients to ensure their nutritional needs are being met – especially NET patients. In my role, it’s challenging to find something that works for each individual case, but when you can give someone the peace of mind that they can enjoy a meal and improve their health, it’s all worth it.

  1. What do you recommend for neuroendocrine tumor (NET) patients experiencing a variety of symptoms?

For NET patients, there is not one single treatment or solution. Everyone is different and recommendations are tailored based on the individual’s history and current medical status.

Because NETs begin in the hormone producing cells of the body and cause symptoms of flushing and diarrhea, patients can have trouble tolerating certain foods. A specific food can help one area, but might trigger another system, so it’s a complex process to find the right balance. With many patients, symptoms can create a snowball-like effect. When patients have diarrhea or feel like they can’t eat, this leads to eating less to try to stop these symptoms. Patients will then experience weight loss and less energy. It becomes more difficult for patients who have experienced advanced disease or have had surgery.

When I meet with a patient, I try to get the best picture of medical history and what they’re currently eating. Many times, we decide to eliminate foods that have a high amine content. Amines are chemical compounds that can trigger neuroendocrine tumors to secrete substances that cause flushing or diarrhea. Amines can be naturally occurring in foods, including fruits, vegetables, aged foods (cheese), or other proteins. While sometimes these foods can trigger symptoms, not everyone is sensitive to them. A lot of times we discover that patients can have certain types of food, but have avoided them in the past because they’ve been afraid of a reaction. Enterade, an amino acid and electrolyte medical beverage, has been a great addition to patients’ regimens and helped control diarrhea and just feel better. It’s a great supplement to what we’re already doing nutrition-wise for the patient.

  1. Can you share any positive experiences you’ve encountered with patients? 

I’m happy to say I’ve seen many success stories! I’ve seen NET patients regain control of their life again and return to the things they enjoy after using enterade. Some patients have gone from using the bathroom 10 times a day to only 3 – which is a huge impact on their lives. One patient is able to drink one bottle of enterade at night, and can wake up the next day and have her morning coffee stress-free. Individuals can go out to eat at a restaurant without immediately scoping out the building for a bathroom.

Many patients are treated with a somatostatin analogue – which can be a monthly injection to treat NETs or carcinoid cancer. Around the time of injection, a patient’s diarrhea can become worse for a week or so. Patients who have used enterade during that specific time helped to reduce the frequency and urgency. By using enterade, one patient was able to play in her softball game after she received her injection!

One of the great things about this beverage is that it can be tailored to an individual’s needs and is not a prescription. Some just drink enterade when they have more symptoms, or take it once a day. It not only replenishes you, but improves the way your body functions and enhances quality of life. There is a lot of life to live. Some of the small things we take for granted, we can change and improve for others.

  1. Are there foods that NET patients should typically stay away from?

I don’t tell patients to stay away from one type of food right away. Just because an avocado or banana triggers a bad reaction in one person, it doesn’t mean the next person will experience the same thing. Patients sometimes restrict too much from their diet from reading generalized lists on nutrition. The diarrhea that NET patients experience is different and more complicated than other instances of diarrhea, so it really requires a full review of a patient’s history and discussion of what has or hasn’t worked in the past.

  1. Are there any common misconceptions or myths that you want to dispel? 

There is so much information out there, so it’s hard for patients to weed through everything and determine what is actually backed up by scientific evidence. A lot of times, patients receive anecdotal stories about what has worked for other people. Friends and family will share information because they want to help. While the intention is in a good place, it doesn’t mean that it will have the same positive effect on you. Talk to your healthcare team to determine what’s best for you and make the best – and informed – decision.

We want patients to be healthy, but also enjoy their food. When there are too many restrictions in place, it limits that. I don’t want people to be afraid to eat. I don’t believe in one food that all NET patients should stay away from because everyone is different. When something is on a “no” list, but it doesn’t bother you and is healthy, I say let’s try it. For those who want to enjoy a dessert once in a while, that’s OK too. My goal is to help control symptoms by working on your diet and finding the right balance. By adding enterade in addition to necessary dietary regimens, we can help improve digestion and hopefully help you to get back to living your life.

  1. Any other tips for people after a NET diagnosis?

I encourage patients to try different things while working with their nutritionist or healthcare professional. While it might be exhausting at first, we need to find what works. There may be some trial and error in the beginning, but stay with it until we find the right solution for you based on your needs. It’s exhausting for NET patients to have to worry about food and what they’re eating. That’s where I come in to do my job and alleviate this one aspect of their lives. There is help, there is hope.

You can find more information about Enterade and how to order by clicking here.

Special Offer! Use promo code “NCAN” to receive 10% off your purchase of enteradeR. enteradeR is a sugar-free, amino acid beverage that can help reduce frequency of diarrhea in NET patients. In addition, enteradeR is donating 25 cents for every bottle purchased to NCAN. enteradeR is available in orange and vanilla flavors – no prescription needed. Offer ends at 12 pm ET on January 1, 2019. To purchase, visit:

2018 NCAN National NET Cancer Patient Conference



When: Thursday, September 27, 2018, 12PM – Saturday, September 29, 2018, 5PM

Where: Green Valley Ranch
2300 Paseo Verde Pkwy, Henderson, NV 89052

Cost: $125 per person

The 2018 National Neuroendocrine Cancer Patient Conference is right around the corner!

Mid-gut noids, Lungnoids, P-NET patients, Whipple patients and OTHER NET PATIENTS- get ready for another fantastic lineup. Some of the topics are brand-new, sprinkled in with advice from the EXPERTS on the top issues faced by NET patients.

Build your knowledge and become a better advocate for your health! Please join us for the most exciting and informative patient conference of 2018! 2-1/2 days, 20 experts on neuroendocrine cancer, over 500 patients and their families, awesome presentations and panel discussions and networking, networking, networking PLUS some fun activities too. It’s a can’t-miss experience.

Take a look at our great line-up HERE and register HERE!

Keep your eyes out for profiles on our fabulous presenters coming soon!!

Announcing NCAN’s 2018 National NET Patient Conference…

NCAN’s 2018 National NET Patient Conference will be in Las Vegas, Nevada, Thursday, September 27th through Saturday, September 29th, 2018. All events will be held at the Green Valley Ranch.

You can check out the Green Valley Ranch here.

Keep your eyes out for all the information to come in the next few months as we prepare to open registration January 2018! We look forward to sharing another great National NET Patient Conference with top doctors giving us the most up-to-date information on NET Cancer!





The Neuroendocrine Cancer Awareness Network (NCAN) is excited to announce their new branch, NCAN NETCARE.

NCAN NETCARE is the newest addition to the NCAN family in the continuing efforts to meet the needs of the Neuroendocrine Community. NCAN NETCARE will host accredited CME and CMU programs to reach and continue education of Neuroendocrine Cancers to physicians and nurses.

After years of working towards this expansion, NCAN and NCAN NETCARE are happy to announce their first CME program coming this June in joint production with Stony Brook University, School of Medicine, Office of Continuing Medical Education (OCME) the Accredited Provider, to present Neuroendocrine Tumor Management: Evolving Therapies & Approaches on June 10th, 2017 being held at the Melville Marriott, 1350 Walt Whitman Road, Melville, NY 11747. Neuroendocrine Tumor Management: Evolving Therapies & Approaches will be a CME Catagory 1 credit worth up to 5.00. Registration for Neuroendocrine Tumor Management: Evolving Therapies & Approaches will open April 25th, 2017.

NCAN and their board has expanded on the importance of why they have decided to grow into this space:

“Over the last seven years, there has been dramatic change in the neuroendocrine (NET) field. There have been several large randomized phase III trials of novel treatments completed resulting in new drug approvals. In parallel, there has been an increased understanding of specific biological pathways implicated in neuroendocrine tumor growth. Additionally, significant developments in diagnosis, loco-regional and systemic therapy are rapidly being developed. Consequently, there is a clear need for physicians and allied health care providers to learn about the management options for patients with neuroendocrine tumors, how to sequence treatments and familiarize themselves with new therapeutic, surgical and regional approaches to these diseases.

In light of these rapid developments, we are producing these meetings to draw medical professionals who treat NET patients with the aim of disseminating new information and discussing key clinical trials goals. The intent of the conference is to provide up to date evidence based practice to health care professionals involved in the diagnosis, treatment and management of the patients living with these malignancies. Ultimately this will result in a tremendous benefit to the patient population by improved outcomes and survival.”

More CME and CMU programs will be available throughout the year! Keep an eye out and spread the word to your doctors as these important programs roll out.

NCAN has more exciting and important news to share very soon. Watch for these updates in the coming weeks!

NCAN on Happy Sunday Morning LIVE

This morning, Maryann and Bob Wahmann of NCAN made a live appearence on WLINY Studios LIVE show Happy Sunday Morning with David Gussin to discuss Neuroendocrine Cancer, NCAN, and many upcoming projects and events coming in the NET community!

They also discussed the REAL reason behind choosing the zebra to represent Neuroendocrine Cancers!

You can check out their segment on Happy Sunday Morning with David Gussin HERE! (NCAN segment beginning 24:35 minute mark!)


NCAN would like to send a BIG Thank You to David Gussin and WLINY Studios LIVE for helping spread awareness of Neuroendocrine Cancers and helping NCAN spread the word of our mission!

Help Get NET Cancer Awareness BLOOMING This Spring!

Help us, the Neuroendocrine Cancer Awareness Network (NCAN), get NET Cancer Awareness BLOOMING this spring by purchasing beautiful flowers for your garden!

NCAN is doing a flower fundraiser this month to get awareness for NET Cancer blooming this spring!

How you can help: Visit NCAN’s fundraising site here and purchase blubs and seeds of your favorite flowers! Then, you will recieve your flowers and NCAN will recieve a whopping 50% profit from your purchase!

How it works: This campaign is running today (March 1st, 2017) through April 30th, 2017. You can place your order beginning now!

Please help us reach our goal of $2500 this spring so NCAN can continue the amazing and tireless work they do throughout the whole year! Remember once you make your purchase, be sure to send the campaign link on to friends and family, as well as sharing on social media such as Facebook!

We thank you for your support and for helping us BLOOM awareness for NET Cancer! Happy shopping and HAPPY SPRING!




First-In-Class: Tryptophan Hydroxylase Inhibitor Orphan Drug XERMELO Now Available to Treat Rare and Debilitating Condition Characterized by Frequent, Severe Diarrhea

Conference Call and Webcast at 5:00 pm Eastern Time

The Woodlands, Texas, February 28, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved XERMELO™ (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapyi. Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors (mNETs)ii. XERMELO targets the overproduction of serotonin inside mNET cellsiii, providing a new treatment option for patients suffering from carcinoid syndrome diarrhea. This new treatment is now available by prescription and will be in select specialty pharmacies beginning March 6, 2017.

“Today’s approval of XERMELO represents a shift in the treatment paradigm of carcinoid syndrome diarrhea for cancer patients who are inadequately controlled by SSA therapy, and until now, have had limited options to manage this debilitating condition,” said Lonnel Coats, Lexicon’s president and chief executive officer. “We are proud to have discovered and developed this ground-breaking orphan drug, and it is an honor to make it available for the thousands of patients currently suffering from this condition who wish to lead a more routine life with fewer incidences of severe diarrhea.”

Carcinoid syndrome is a rare condition that occurs in patients living with mNETsiv and is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives, as well as by facial flushing, abdominal pain, fatigue and, over time, heart valve damage.

“The approval of XERMELO establishes a new treatment option for patients with carcinoid syndrome diarrhea that is inadequately controlled by SSA therapy,” said Matthew H. Kulke, M.D., TELESTAR primary investigator, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana Farber Cancer Institute and Professor of Medicine, Harvard Medical School. “Inhibition of tumoral serotonin production represents a novel approach for patients with this condition. Studies have shown that XERMELO can reduce the debilitating effects of carcinoid syndrome diarrhea and has a favorable efficacy and safety profile in patients who currently have limited treatment options.”


Discovered using Lexicon’s unique approach to gene science, XERMELO is the first and only approved oral therapy for carcinoid syndrome diarrhea. XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within mNET cells.

Lexicon has built the in-house capability and infrastructure to launch and market XERMELO in the U.S., where it retains all commercialization rights. Lexicon also retains rights to market telotristat ethyl in Japan. Lexicon has established a license and collaboration agreement with Ipsen to commercialize telotristat ethyl in Europe and other countries outside of U.S. and Japan. For more information about XERMELO, please visit

XERMELO™ Important Safety Information

  • Warnings and Precautions: XERMELO may cause constipation which can be serious. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe persistent or worsening abdominal pain develops.
  • Adverse Reactions: The most common adverse reactions (5%) include nausea, headache, increased GGT, depression, peripheral edema, flatulence, decreased appetite, and pyrexia.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 substrates, as XERMELO may decrease their systemic exposure.

For more information about XERMELO, see Full Prescribing Information at

Lexicon Conference Call

Lexicon management will hold a conference call to discuss the approval of XERMELO at 5:00 pm Eastern Time today, February 28, 2017. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 78166536. Investors can access a live webcast of the call at An archived version of the webcast will be available on the website through March 31, 2017.

About Lexicon

Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in diabetes and metabolism and neuropathic pain. For additional information please visit

In an effort to ensure all appropriate patients have fast access to affordable treatment, Lexicon offers LexCares—a comprehensive program designed to guide patients through each step of their treatment journey. Through LexCares, patients will have access to financial assistance programs that may reduce or eliminate out-of-pocket costs associated with their XERMELO prescription. For additional information about the LexCares program, visit

Safe Harbor Statement

This press release contains “forwardlooking statements,” including statements relating to the safety and efficacy and the therapeutic and commercial potential of XERMELO (telotristat ethyl) 250 mg. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forwardlooking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the degree of market acceptance of XERMELO, the availability of coverage and reimbursement for XERMELO, Lexicon’s dependence on third parties for manufacturing and distribution of XERMELO, Lexicon’s compliance with applicable legal and regulatory requirements and other factors relating to the commercialization of XERMELO. Other risks include Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other potential drug candidates, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forwardlooking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forwardlooking statements, whether as a result of new information, future events or otherwise.

# # #

To read the full press release from Lexicon: xermelo-fda-approval-release-final

Five Reasons to Attend a Neuroendocrine Cancer Patient Conference

Educational opportunities. No matter how experienced you are about handling your disease, everyone can learn. Being treated for a rare cancer can often be isolating, and without exposure to a variety of points of view, we can miss new ideas and trends that can impact our futures. The educational aspect of a conference can expose you to new treatment regimens and therapies and help you discover how to be a more productive advocate for your treatment and care.

Networking with peers. Patient conferences provide a great opportunity to network. Often patients and caregivers from different regions of the country can become valuable resources for referrals and best-practices. Avoiding your peers for whatever reason you have can actually limit you own success in fighting neuroendocrine cancer. You will find that the people who come together at a conference can help each other uncover ideas and spark inspiration when they get to know each other on a personal level.

Encounter the vendors & suppliers who provide the therapies you need. Too often people shy away from exhibitors at conferences. They fear they will have to talk to salespeople, but these industry suppliers are some of the best people for you to get to know if you want to learn more about the current direction of treatment. Discovering innovative products and services for your business is critical to your treatment and care in today’s fast-paced world. Invest time with the sponsors at the event and turn them into your friends and allies.

Position yourself as an expert. It has been suggested that well over half the requests by neuroendocrine cancer patients to their physicians for specific treatments are honored. A neuroendocrine cancer patient conference is the perfect opportunity to build your knowledge and become a better advocate for your health! You will hear directly from experts. Save your life by making sure you know enough to participate in your care so you are getting the best treatment plan possible.

Have fun. Being a neuroendocrine cancer patient or caregiver is hard work and it is stressful. All work and no play can get old fast. Patient conferences can add a layer of enjoyment to managing your disease by mixing a social aspect into your patient journey. Taking an extra day at the beginning or end of the trip to explore or visit friends in the region is also a great way to maximize the investment in travel. Never underestimate the power of a little fun mixed with some interesting people!

The internet won’t replace the conference experience. Many falsely believe that since they can now access industry information via the internet that the days of the live meeting are gone. The truth is, meetings are more important than ever. The value in meetings comes from the human-to-human connections that occur. Often people cite the serendipidous “hallway-conversations” that they have with other attendees as the most valuable parts of attending an event. While these are not on the agenda, or mentioned in the learning objectives, when two or more people begin to discuss topics on a deeper and personal level, the success of the event to those involved becomes irreplaceable. It is the people that bring the ROI to your time at a conference.

NCAN has 4 conferences scheduled for 2017. Why not make it your business to attend at least one of them?

Saturday, March 25th – NET Patient Conference – Charlotte, NC (Registration open NOW!)

Saturday, April 22nd – NET Patient Conference – Lexington, KY (Registration open NOW!)

Saturday, May 6th – NET Patient Conference – Seattle, WA (More information to come!)

Saturday, October 14th – NET Patient Conference – Iowa City, IA (More information to come!)

NCAN’s 2017 Kentucky Neuroendocrine Cancer Patient Conference

Registration is open for the 2017 Kentucky Neuroendocrine Cancer Patient Conference & support group meeting on April 22nd, 2017 in Lexington, KY!

Date & Time: Saturday, April 22nd, 2017 from 8AM-5PM

Where: Griffon Gate Marriott Resort & Spa – 1800 Newtown Pike, Lexington, KY 40511

Price: $20 per person – includes breakfast, lunch, & snacks


8:00 am – 8:30 am     Registration and Breakfast

8:30 am – 8:45 am     Welcome By: Robert Wahmann          

9:00 am – 9:45 am     Controlling Symptoms of Hormone Hypersecretion By: Lowell Anthony, M.D.

 9:45 am – 10:15 am     Improvements in NET Imaging By: Riham El Khouli, M.D.

 10:15 am – 11:00 am     What is PRRT?  Results of the Randomized Phase III Clinical Trial By: Larry Kvols, M.D.

 11:00 am – 11:15 am     Break

 11:15 am – 11:45 am     Clinical Trials in NET  By: Aman Chauhan, M.D.

 11:45 am – 12:30 pm     Questions and Answers

 12:30 pm – 1:30 pm     Lunch

 1:30 pm – 2:30 pm     Patient Experiences

 2:30 pm – 4:00 pm     Support Group Session

For more information and to by YOUR ticket to the 2017 Kentucky Neuroendocrine Cancer Patient Conference on Saturday, April 22nd, click HERE!

Produced by: NCAN Bandaid

Don’t Miss the 2017 Charlotte NET Patient Conference!

NCAN has officially opened up registration for the 2017 Charlotte NET Patient Conference for Saturday, March 25th, 2017!


8 AM – 9 AM     Registration and Breakfast

9 AM – 9:10 AM     Welcome- Tricia Wahmann, NCAN

9:10 – 9:45 AM     Surgery and Related Therapies for NET Liver Metastasis- David Iannitti, MD

9:45 – 10:15 AM     NET Clinical Trials- Reza Nazemzadeh, MD

10:15 – 10:30 AM     Break

10:30 AM – 11:00 AM     Treating NETS: A Gastroenterologist’s Perspective-Matthew Eves, MD

11:00 – 11:30 AM     New Medical Treatment Options for Carcinoid / NET Cancer Patients- Brian Morse, MD

11:30 – 12:30 PM     Question and Answer

12:30 – 1:30 PM     Lunch

1:30 PM – 2:30 PM     The Significance of Patient Advocacy- Maryann Wahmann, Ronda Ayala, Judy Golz

2:30 PM – 2:45 PM     Break

2:45 PM – 3:45 PM     Networking for Patients

Meet the Speakers:

David Iannitti, MD- Surgery

Dr. Iannitti is the Chief of Hepatobiliary and Pancreatic (HBP) Surgery. In addition to clinical research in the area of surgical approaches to treat diseases of the digestive tract, he is engaged in basic research that focuses on the development and characterization of microwave ablation technology for the ablation of tumor masses. Dr. Iannitti also collaborates closely with Dr. McKillop in ongoing projects that address the fundamental pathophysiology of Hepatocellular carcinoma development and progression. Dr. Iannitti also oversees the HBP Fellows program at CMC including the research and clinical components. 

Reza Nazemzadeh MD- Medical Oncology

Dr. Nazemzadeh graduated from the University of Texas Medical School at Houston in 2000. He works in Charlotte, NC and specializes in Hematology/Oncology. Dr. Nazemzadeh is affiliated with Carolinas Medical Center.

Matthew Eves, MD- Gastroenterology

Dr. Matthew Eves is a gastroenterologist in Mobile, Alabama and is affiliated with multiple hospitals in the area, including Huntsville Hospital and Mizell Memorial Hospital. He received his medical degree from University of South Alabama College of Medicine

Brian Morse, MD- Radiology

Dr. Morse is an Assistant Member in the diagnostic Imaging section of Moffitt Cancer Center and holds a co-appointment as an Assistant Professor in the Department of Oncologic Sciences at the University of South Florida.  He received a BA in Microbiology from the University of Texas at Austin and an M.D. from the University of Texas Health Science Center at San Antonio.  He completed his radiology residency at the University of Texas Southwestern Medical Center at Dallas where he served as radiology chief-resident during his final year.  After residency, Dr. Morse completed fellowship training in cross-sectional imaging with an emphasis in body MRI at the Mayo Clinic in Scottsdale, Arizona.  Dr. Morse is a reviewer for several journals and has published multiple articles in peer-reviewed journals.  His clinical expertise includes the use of computed tomography (CT), magnetic resonance imaging (MRI), radiographs and fluoroscopy to diagnose cancer and assess treatment response, particularly of the gastrointestinal and genitourinary organs.  His research interests focus on imaging of neuroendocrine tumors.

Important information about this conference:

Where: Charlotte Marriott SouthPark – 2200 Rexford Road, Charlotte, NC 20211

Cost: $20 includes: breakfast, lunch, and breaks.

Special Rate for the hotel is available when booked BEFORE March 3rd. $129/night. You can book your room here!

Self-Parking is FREE.

To sign up for your spot at the 2017 Charlotte NET Patient Conference on Saturday, March 25th, 2017, please click here!